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Abstract
Formality in Quality Risk Management (QRM) is an interesting concept. What makes a QRM activity
‘formal’ and what makes one ‘informal’? A simplistic viewpoint might be that formal is when a QRM
tool is used to manage risks, and informal is when no such tool is used. But is it that simple? And are
there different degrees of formality in QRM - is it a spectrum, or is it a binary concept? These
questions are explored in this paper. Since the introduction of ICH Q9 in 2005, there have been
discussions in the pharmaceutical industry and between regulators regarding the concept of
formality in QRM. ICH Q9 presents two principles of Quality Risk Management, and one of those
refers to formality – it states that “the level of effort, formality and documentation of the quality risk
management process should be commensurate with the level of risk”. What formality in QRM
means at a practical level is currently not clear. A lack of understanding of this concept has probably
led to certain negative consequences – ranging from a lack of scientific rigour being applied during
certain complex risk assessments, to the overuse of quite resource intensive and highly formalized
QRM activities to address relatively straight forward GMP problems and risk questions. In response
to this lack of clarity, regulators and industry representatives initiated work to explore the concept
of formality in QRM, with a view to achieving a shared understanding as to what it means at a
practical level. It was of interest that there was strong support expressed among industry and GMP
inspectors for the use of less formal approaches to QRM. The primary outcome of that work is a set
of suggested definitions for formal and less formal approaches to QRM. There are several
anticipated benefits to this work – including that a better understanding of formality may lead to
resources for QRM being used more efficiently – where lower risk issues are dealt with via less
formal means, freeing up resources for managing higher risk issues and more complex problems,
which usually require increased levels of rigour and effort.
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1. Introduction - Why discuss formality in Quality Risk Management?
Understanding formality in QRM is not just of academic interest - it is of practical relevance
to the day-to-day application of QRM in pharmaceutical manufacturing and control. This is
because the guideline that has served as the basis for most risk-based approaches in the
pharmaceutical industry for the past 15 years, ICH Q9 (1), places formality (alongside other
concepts) firmly at the centre of QRM. ICH Q9 indicates that, although ‘a systematic
approach to quality risk management is generally preferred, it is neither always appropriate
nor necessary to use a formal risk management process’. It indicates that the use of
‘informal risk management processes may also be acceptable’.
ICH Q9 presents two principles of quality risk management:

•

The evaluation of the risk to quality should be based on scientific knowledge and
ultimately link to the protection of the patient, and

•

The level of effort, formality and documentation of the quality risk management process
should be commensurate with the level of risk.

With regard to the reference to formality in the second principle, it is useful to consider
what this means at a practical level, as, while it may seem intuitively easy to grasp, our
experience is that the concept of formality in QRM is not so straight forward. Our research
has found that it remains unclear to many practitioners in the pharmaceutical industry, and
to many GMP Inspectors too, just what formality in QRM actually means, and what differing
levels of formality might look like in practical terms. The purpose of this paper is to present
our work in this area and to put forward suggested definitions for formal and less formal
approaches to QRM, in an effort to bring clarity to this concept. A greater understanding of
formality in QRM has the potential to lead to more fit-for-purpose applications of QRM, the
better use of resources for such work, more effective, scientific and data-driven risk
assessment outputs, and an improved level of GMP compliance overall.
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2. Exploring the Concept of Formality in Official Guidance and Standards
The use of formalised Quality Risk Management (QRM) approaches in the pharmaceutical
manufacturing sector was catalysed by the publication of ICH Q9 in late 2005. Since then,
and with the publication of the ICH Q8(R1) (2), Q10 (3), Q11 (4) and more recently the Q12
(5) guidelines, there has been a steady move towards risk-based approaches in the industry
generally.
As noted above, the concept of formality is embedded in one of the two core ICH Q9
principles of QRM. Apart from that, the guideline makes several other references to
formality in QRM too. In its introductory section, for example, it states: “It is neither always
appropriate nor always necessary to use a formal risk assessment process (using recognised
tools and/or internal procedures, e.g. SOPs).

The use of informal risk management

processes (using empirical tools and/or internal procedures) can also be considered
acceptable.” (1) This statement indicates that the use of empirical tools constitutes informal
approaches to QRM, whilst the use of recognized tools constitutes formal approaches. It
also indicates that internal procedures can constitute both formal and informal approaches.
The section in ICH Q9 on Risk Control also refers to formality; it states that risk acceptance
“can be a formal decision to accept the residual risk or it can be a passive decision in which
residual risks are not specified.” (1)
The section titled ‘Risk Management Methodology’ states that, traditionally, “risks to quality
have been assessed in a variety of informal ways (empirical and/or internal procedures)
based on, e.g., compilation of observations, trends and other information” and that such
approaches “continue to provide useful information that might support topics such as
handling of complaints, quality defects, deviations and allocation of resources.” (1) It goes
on to state that, additionally, “the pharmaceutical industry and regulators can assess and
manage risk using recognised risk management tools and/or internal procedures (e.g.
SOPs)” and a list is provided in the guideline of some of those tools. (1)
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Based on the above, it is evident that ICH Q9 places the use of recognised tools at the heart
of formal approaches to QRM. There are many tools available that may be used to support
and/or perform Quality Risk Management-related activities. These include Preliminary
Hazard Analysis (PHA), Hazard and Operability Studies (HAZOP), Fault Tree Analysis (FTA),
Failure Modes and Effects Analysis (FMEA), Failure Modes, Effects and Criticality Analysis
(FMECA), Hazard Analysis and Critical Control Points (HACCP), among others. The available
tools differ widely in design - some lead to qualitative assessments of risks (e.g. Preliminary
Hazard Analysis), whilst others are quite complex, highly structured and rule based, such as
the Probabilistic Risk Assessment techniques that are often used by nuclear power plants
and which involve the use of complicated mathematical concepts such as Monte Carlo
simulations when arriving at probabilistic expressions of risk (6, 7).
Other tools lie somewhere in the middle, such as FMEA (Failure Modes and Effects Analysis)
and HACCP (Hazard Analysis and Critical Control Points), which, at best, provide for semiquantitative risk ratings, although one could argue that those particular tools are perhaps
more qualitative than quantitative, even when they generate numerical expressions of
relative risk in the form of Risk Priority Numbers (RPNs), (8) The reason for this is that RPN
numbers are usually arrived at via the multiplication of what are called ordinal scale
numbers. These are numbers that indicate relative positions on a scale (e.g. on a probability
scale of 1 to 5, 4 is higher than 2, but it may not represent double the probability of an
event occurring).

With ordinal scale numbers, their magnitude (and thus their

multiplication) is not meaningful in a mathematical sense (9, 10, 11).
In addition to considering the use of QRM tools, might formality in QRM be related to how
risks are assessed? When risks are based on estimates of the probability of occurrence of
hazards or failure modes, the severity of their potential effects, and the detectability of
those hazards or failure modes, does that make it a formal approach to QRM? And when
risk estimates are not based on those factors, does that make the approach informal? This
is useful to think about.
Are there different degrees of formality in QRM? Is it a spectrum, or is it a binary concept?
The section in ICH Q9 titled ‘Risk Management Methodology’ states that the “degree of
4
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rigor and formality of QRM should reflect available knowledge and be commensurate with
the complexity and/or criticality of the issue to be addressed” (1). This links formality with
knowledge, complexity and criticality, which are useful considerations, and the reference to
the ‘degree’ of formality suggests that there may be a spectrum of formality, rather than it
being a binary thing.
Several Risk Management standards and other official guidelines also refer to formality. The
2010 WHO guideline on QRM (12), for example, makes several references to formality, and
is perhaps the publication that deals most comprehensively with this concept. For example,
in relation to inspecting the QRM system at pharmaceutical manufacturers, the guideline
indicates that inspectors should be “pragmatic regarding the level of scrutiny and degree of
formality required for any given situation”, and it states that “the procedures for risk-based
decisions and formality of approach should be commensurate with the level of patient risk”.
The WHO guideline also requires critical issues to be addressed “with appropriate high
urgency and formality”. In the section on Risk Communication and Documentation, the
guideline indicates that it is not necessary to issue “a full report for every risk assessment”,
and that “the level of effort, formality and documentation of the QRM process can be
commensurate with the level of risk”. It goes on to state that an organization “can be
pragmatic regarding the degree of formality that is required; however, appropriate evidence
of mitigating activities should be available, and a written output must be retained.” The
guideline also indicates that “increased formality and detail” is expected for more significant
risks. (12)
It is interesting that, despite its highly structured approach to risk management, the ISO
standard on the use of risk management in relation to medical devices, ISO 14971:2019 (13),
makes only two brief references to formality – one is in a note about records, which
indicates that records serve as a means to formalize traceability. The second relates to risk
management plans, which are required by the standard to describe the “activities related to
collection and review of relevant production and post-production information”.

The

standard indicates that the reason for this is the need for “a formal and appropriate way to
feedback” such information “into the risk management process” (13).
5
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The International Standard ISO 31000:2009, titled Risk Management – Principles and
Guidelines (14), also refers to formality. Its Introduction section indicates that “when a
formal process is in place within an organization for particular types of risk or circumstances,
the organization can decide to carry out a critical review of its existing practices and
processes”. And in the Terms and Definitions section of the Standard, reference is made to
both “formal and informal decision-making processes” as they relate to the internal context
in which an organisation performs its risk management activities (Ref 14).
Taken together, the above references indicate that formality is generally considered an
important concept in risk management and in quality risk management activities, and that
there can be different degrees (or levels) of formality.

3.The benefits of having clear definitions for what Formal & Less Formal QRM mean
The references to formality in ICH Q9 and other official publications indicate the important
role that formality plays when assessing and managing risks, but it is also useful to consider
the benefits that increased clarity for this concept may bring. There are several benefits
that can reasonably be anticipated:

•

Clarity around formality in QRM can help ensure that the extent of scientific and
methodological rigour that is applied during QRM activities is commensurate with the
level of risk.

•

Business resources for QRM can be more efficiently allocated in accordance with the
level of potential risk that needs to be managed – lower risk issues can be dealt with
more efficiently via less formal means, and this can free up resources for managing
higher risk issues which usually require increased levels of rigour and effort.

•

A better understanding of formality in QRM may lead to a more pluralist approach when
selecting the most appropriate tool for a given QRM activity –where an increased
6
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understanding will allow selection of the most appropriate tool for the situation at hand,
instead of defaulting to a standard tool (e.g. FMEA) regardless of the complexity of the
risk question at hand or the complexity of the process or activity being risk assessed. It
is important to note also that different QRM tools and approaches can involve differing
levels of rigour, and increased clarity around formality may help users select the most
appropriate tool or approach in a given situation.
4.Characterising Formality in QRM activities – Initial Industry / Regulator work, 2016-2017
Following discussions in 2016 between the Health Products Regulatory Authority (HPRA) in
Dublin, Ireland, the Pharmaceutical Regulatory Science Team (PSRT) at the Technological
University, Dublin, McGee Pharma International and the Irish Chapter of the Parenteral Drug
Association (PDA), two workshops were run with representatives from pharmaceutical
manufacturing companies in Ireland to explore the meaning and practical application of
formality in QRM activities.
A total of 80 staff from 50 pharmaceutical companies attended the workshops; these
included staff from several large biotech manufacturing sites, as well as staff from small
molecule API sites, non-sterile and sterile finished non-biological product sites, amongst
others.
The first workshop (November 2016) focused on a number of key questions and issues,
including:
•

How can different degrees of formality in QRM be applied whilst still effectively
managing risks to product quality?

•

Will regulators accept informal approaches to QRM?

•

When is it appropriate to apply informal QRM in a GMP setting?

•

What QRM tools, if any, would be considered to be informal approaches?

•

What are the benefits of using informal approaches over formal ones?

•

Can informal QRM be used to support qualification and validation activities?

•

Can a company use informal risk assessments to comply with EU GMP Annex 15
requirement that, the way in which “risk assessments are used to support validation
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activities should be clearly documented”? Or, are companies required to use more
formal approaches in this area?
•

How would a company document its informal QRM activities?

Work was undertaken to develop a set of keywords that could be used to describe what was
meant by formal and informal QRM, and the flowchart shown in Figure 1, which had been
included in an ICH Q9 briefing pack (15) on Quality Risk Management and which referred to
both formal and informal risk management, was reviewed and discussed. (For a review of
this flowchart, please see Appendix 1.)

Figure 1: Slide from ICH Q9 Briefing Pack that refers to Formal and Informal Risk Management

The second workshop (March 2017) further explored the issues raised at the first workshop,
and it then focussed on characterising what may be meant by formal and informal QRM.
Overall, it was evident from the workshops that there was significant uncertainty about
what constituted formality in the context of QRM. There was a lack of clarity on what tools,
if any, should be considered less formal compared to other tools and approaches, and in
what situations they might be applied. While a set of keywords was developed which
illustrated to some extent what might be meant by formal QRM and informal QRM, it was
8
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far from cohesive, it was sometimes contradictory, and it was generally difficult to interpret.
It was agreed that the topic of formality in QRM was of direct relevance and interest to
medicines manufacturers, and that clearer regulatory guidance in this area was needed.
For a more complete description of the two workshops and their outputs, please see
Appendix 1.

5.Industry / Regulator Working Group on Formality in QRM, 2017-2020
Towards the end of 2017, after the two aforementioned-workshops had been held, a small
group of QRM practitioners formed a working group to further explore the concept of
formality in QRM. This group was comprised of representatives from two pharmaceutical
companies (Jazz Pharmaceuticals and MSD), as well as representatives from the HPRA, the
medicines regulatory authority in Ireland, Over the course of 24 months, the working group
met several times and, as its discussions evolved, it worked on the following goals:

•

To generate insights into the concept of formality in QRM which might support the
development of future guidance on this topic.

•

To encourage more effective QRM applications by the industry and regulators alike, by
showing how a better understanding of formality in QRM might help to deliver more
value-added and evidence based QRM outputs and a better use of resources, where
effort is more commensurate with the level of risk.

•

To demonstrate the benefits of collaboration between industry and regulators in order to
drive continuous improvement in GMP/Regulatory Guidance at a global level.

Upfront, the working group reviewed the discussions and the outputs from the PDA Ireland
Chapter workshops in November 2016 (Cork, Ireland) and March 2017 (Dublin, Ireland), and
key learnings from those were extracted and documented. The available guidance and
literature was reviewed again, and the experiences of the two companies and the regulators
in relation to formality in QRM were shared.
9
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6. Survey with GMP Inspectors on the Concept of Formality in QRM,
September 2018
After the working group had distilled and documented its thinking on what constituted
formality in QRM, a survey was carried out with GMP inspectors during a PIC/S QRM
meeting held in Taiwan in September 2018. This explored their understanding and views
about the concept of formality in QRM.
A total of 27 GMP Inspectors from 14 different countries completed the survey. The
countries in question were: Austria, Indonesia, Iran, Ireland, Italy, Malaysia, Saudi Arabia,
Singapore, Slovenia, Sri Lanka, Switzerland, Taiwan, the United Kingdom and the United
States, and the following is a summary of the survey’s main findings:
•

85% of the respondents stated that, if ICH Q9 were to be revised, they would like the
revision to clarify what is meant by formal QRM and informal QRM.

•

Only 22% indicated that they had a good understanding of the concepts of formal
QRM and informal QRM; a higher number (30%) indicated either little understanding
or a very poor level of understanding in this area. 41% rated their level of
understanding as moderate, and 7% did not give a rating.

•

81% of the respondents indicated agreement and support for the use of informal risk
management processes. 11% did not, and 8% said they didn’t know.

•

In relation to how formal and less formal QRM might be characterised, as presented
earlier in this paper, 74% expressed agreement with all, of most parts, of those
definitions. 11% of the respondents disagreed fully or partially with them, and 15%
remained neutral.

•

The inspectors were asked if there was a need for additional guidance for GMP
inspectors (and for the industry) on what is meant by formal QRM and informal
QRM. Of the 25 respondents who answered this question, 76% stated that
additional guidance was required. 12% stated that additional guidance was not
required and 12% said they didn’t know.

Overall, the survey results indicated that, while there was clear support among the GMP
inspectors for the use of different levels of formality in quality risk management activities,
there was also a need for clarity and guidance on what is meant by formal QRM and less
formal applications of QRM. There was strong support for the suggested way in which
formal QRM might be characterised and for what might constitute lower levels of formality.
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7. Suggested Definitions for Formality in QRM
The informal working group on formality in QRM completed its work by a) developing a set
of simple definitions on the concept of formality in QRM (see Table 1), and b) writing this
paper as a means to communicate those definitions and encourage wider discussion on this
topic. The definitions for Formal QRM and Lower Levels of Formal QRM were arrived at
following a review of the work completed and the learnings made up to that point, as well
as the use of a structured approach involving a What, When and How methodology. When
developing the definitions, various elements were considered, including QRM procedures,
risk assessment and QRM tool selection, training considerations, documentation
requirements, issues associated with level of effort, and of course the guidance available in
the current version of ICH Q9. At the outset, it was agreed that the definitions had to be
brief, concise and easy to understand.
Suggested Definitions for Formality in QRM
Formal QRM may be characterised by the following…
• The QRM process is proceduralised, systematic and includes all the elements of QRM as per
ICH Q9 (Risk Assessment, Risk Control, Risk Review and Risk Communication).
• A stand-alone QRM report is generated, which documents all aspects of the QRM process and
which meets current GMP documentation expectations.
• A cross functional team is in place for the QRM activity. (Note that having an independent
facilitator on the team may represent best practice.)
• Recognised or customised quality risk management tools are used in some or all parts of the
QRM process – e.g. FMEA, Risk Ranking, HACCP, FTA, Fishbone Analysis, PHA, etc. Note that
the tools can differ in terms of their complexity and degree of rigour.
• All risk scores / ratings are supported by data or by a written justification or rationale. The
ratings and outcomes are based on sound evidence, science and data.
Lower levels of formality in QRM may be characterised by the following…
• Elements of the QRM process (e.g. Risk Assessment) are embedded / integrated into other
parts of the Pharmaceutical Quality System (PQS), such as in the Change Control process, in
the Deviation and CAPA processes, in Validation activities, etc.
• Stand-alone QRM reports may not be generated, but the outcomes of the QRM process are
documented in the relevant part of the Pharmaceutical Quality System.
• A cross functional team may not be required, and risk-based decisions may be made by one or
more people.
• Recognised or customised quality risk management tools are not required to be used in the
QRM process. This means that such tools do not have to be used in order to arrive at
estimates of risk (e.g. high, moderate or low) or when deciding which risks may require
mitigation. However, in informal QRM, such tools may be used in part or in full.
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Published by ARROW@TU Dublin, 2020

11

Level 3, Vol. 15, Iss. 2 [2020], Art. 15
Level3

Issue 17, December 2020

Technological University Dublin

These definitions are fully in line with the general guidance for QRM as per ICH Q9, and they
also reflect key elements of the ICH Q9 briefing pack slide (See Figure 1 above), in that
formal QRM is team based, tool-based, and includes all four elements of the QRM process
as per ICH Q9 – Risk Assessment, Risk control, Risk Review and Risk Communication. The
definitions are also concise and to the point.
The definitions presented here are also supported by the contents of the 2010 WHO
guideline on QRM (12), as well as the ISO standard on the use of risk management in
relation to medical devices, ISO 14971:2019 (13), and the more generic standard on Risk
Management, ISO 31000:2009 (14). For example:
•

In the WHO guideline on QRM, it is stated that an organization can be pragmatic
regarding the degree of formality that is required; however, appropriate evidence of
mitigating activities should be available, and a written output must be retained. This is
reflected in the definitions that are presented here.

•

The ISO standard on risk management for medical devices requires a formal and
appropriate way to feedback information into the risk management process. This is
reflected in the definition for formal QRM presented above – which indicates that the
QRM process is proceduralised and systematic, where all aspects of the QRM process are
documented.

•

In the ISO 31000:2009 Risk Management standard, reference is made to both formal and
informal decision-making processes, and the definitions for formal and less formal QRM
as presented here are reflective of such processes.

Table 2 below provides a high level summary of the above suggested definitions.
QRM characteristics
All four elements of QRM as per ICH Q9 are
applied
Stand-alone QRM reports are generated

Formal QRM
Yes

Cross functional team is used
Use of recognised or customised QRM tools
Risk ratings/scores are supported by data/written
justification/rationale

Yes
Yes
Yes

Yes

Lower Levels of Formality
One or more of the four
elements may be present
Not required, but outcomes
of QRM process are
documented in the PQS
Not required, optional
Not required, optional
Not required, optional

Table 2: Summary of Suggested Definitions for Formality in QRM
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As the above work was underway, an important development within EU regulatory circles
pertaining to formality in QRM (and other issues) had been initiated. The EMA and the
European Commission had initiated work with ICH to trigger a revision of ICH Q9, in order to
provide additional guidance and training materials in certain areas relating to the
application of QRM – and the concept of formality in QRM was one of those areas. In
November 2019, following a number of presentations to various ICH groups, the ICH
Management Committee decided that a revision of ICH Q9 was indeed warranted, and that
this would include work to address the concept of formality in QRM.

8. Conclusions and Recommendations
One of the key principles of QRM as presented in ICH Q9 is that the level of effort, formality
and documentation of the quality risk management process should be commensurate with
the level of risk. What formality in QRM means at a practical level is currently not well
understood, and this has probably led to certain negative consequences – a lack of scientific
rigour being applied during some complex risk assessments, to the overuse of very resource
intensive and highly formalized risk assessment activities to address relatively straight
forward GMP problems.
While ICH Q9 does not provide examples of what formal versus informal QRM mean, the
work presented in this paper shows that there is considerable interest in the industry and
among regulators as to what formality actually means in practical terms, and how the
concept of formality can be applied in everyday GMP situations.
Within this work, we analysed the concept of formality as presented in ICH Q9, in terms of
its practical applications. This work started with two Parenteral Drug Association (PDA)
Ireland workshops, in 2016 and 2017, during which key learning were made in terms of the
difficulties in understanding this concept, in conceptual terms and also in practical ways. It
was of interest that there was strong support expressed among the industry groups for the
use of less formal approaches to QRM – and there was a consensus reached that informal
QRM can be just as effective as formal QRM, if documented appropriately. A small IndustryRegulator working group was then established in late 2017, to continue to explore this issue
13
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and to develop meaningful definitions for what formal QRM and informal QRM might look
like. That working group continued its work intermittently until 2020, and its primary
output is this publication. In a survey performed with GMP inspectors, there was strong
support expressed among the inspectors for the use of less formal approaches to QRM. This
was an interesting finding.
Overall, we found that the concept of formality in QRM is best not viewed as a binary thing
– Formal versus Informal; rather, it is probably best considered along a spectrum, ranging
from high levels of formality to lower levels of formality. The suggested definitions for
formality in QRM presented in this paper reflect this thinking, and in a follow-up paper, they
will be further explored via a number of industry/regulator case studies.

These will

demonstrate the practical application of the suggested definitions presented here, in real
life GMP situations.
There are several anticipated benefits to this work. Additional clarity on the concept of
formality in QRM may help not only ensure that the extent of scientific and methodological
rigour applied during QRM is commensurate with the level of risk, it may also lead to resources for
QRM being used more efficiently – where lower risk issues are dealt with more efficiently via less
formal means, freeing up resources for managing higher risk issues and more complex problems,
which usually require increased levels of rigour and effort.

It is considered that a greater

understanding of formality in QRM has the potential to lead to more appropriate and beneficial uses
of QRM, leading to improved outcomes in terms of pharmaceutical quality, drug availability and
patient health protection.
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Appendix 1 – Summary of two Industry-Regulator Workshops (Nov 2016 and March 2017)
As noted earlier in this paper, two workshops were run with representatives from pharmaceutical
manufacturing companies in Ireland to explore the meaning and practical application of formality in
QRM activities.
•

Workshop No. 1 - November 2016

After reviewing the guidance in ICH Q9 which refers to formality in QRM, a series of questions was
put to the attendees to stimulate discussion and to explore key issues. These questions are shown
on pages 5 and 6. It was evident from the discussions that there was a significant amount of
uncertainty about what constituted formality in the context of QRM. There was also a lack of clarity
on what tools, if any, should be considered to be less formal when compared to other tools and
approaches, and in what situations they might be applied. Some participants stated that it was
simply not known whether regulators would accept informal approaches to QRM, and that this was
an important consideration.
In order to focus the discussions on real-life GMP issues, there was a discussion about the kind of
QRM approach (informal, formal or none at all) that might be applied to two quite different GMP
situations - a change control proposal to install a PAT-based moisture analyser in a granulate drying
process, and a deviation involving a broken metal mesh screen in an API manufacturing process.
The participants were asked to outline the QRM approach they would recommend for the above two
situations, in terms of the risks that might need to be managed and the key questions that would
likely need to be answered, before a decision on the required level of QRM formality could be made.
The discussions were wide-ranging, and a variety of opinions was expressed in relation to how much
QRM formality should be applied to the above two situations. Overall, the outcome was
inconclusive - there was just too little understanding of what constituted formality in QRM in the
first place. This was an interesting finding, and it served to validate our view that additional clarity
and guidance on the concept of formality were required.
During the workshop, an attempt was made to develop a set of keywords that could be used to
describe what was meant by formal and informal QRM. This involved a structured brainstorming
session during which the following questions were put to the attendees:
•
•
•

What is the difference between Risk Assessment and Quality Risk Management?
What five words or phrases would apply to formal QRM?
What five words or phrases would apply to Informal QRM?

The attendees were also asked to complete the following sentences:
• Risk Assessment is highly formalised when….
• Informal Risk Assessment is when….
• QRM is highly formalised when….
• Informal QRM is when….
The above tasks proved challenging - no consensus in terms of keywords was reached and clear and
common interpretations were generally not arrived at either, although a number of associative
keywords were noted. Formal approaches were described using the words and terms such as team,
proactive, predetermined scoring system, documented, quantitative, tools, FMEA, SOPs, and use of a
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facilitator. Informal QRM, on the other hand, was described by the following words and terms:
empirical, no tools, and less formal communication. In some cases, the same words or terms were
used for both formal and informal, for example, ‘SOPs’, ‘documented’ and ‘tools’.
Interestingly, the group did indicate, and with a strong consensus, that informal QRM can be just as
effective as formal QRM, if documented appropriately.
It was also noted that, during the workshop, the attendees generally agreed that each of the
elements of the QRM process as per ICH Q9 (Risk Assessment, Risk control, Risk Review and Risk
Communication) should be regarded as representing formal QRM. The attendees indicated that
formal QRM required a “full loop” approach to those elements - meaning that each of those four
elements should be present and applied if a QRM activity can be regarded as being formal in nature.
When discussing informal approaches, the general view was that the same four QRM process
elements could also apply, but with less formality. Again, this indicated the need for a better
understanding of the concept of formality in QRM, especially what it might mean in practical terms.
The discussion seemed to suggest that, just like with formal QRM, each of the above four QRM
elements should be present before an activity can considered an informal approach to QRM. This
indicated that there was difficulty in understanding how formal and less formal approaches differed
from each other.
The workshop then focussed on reviewing a flowchart that had been included in an ICH Q9 briefing
pack (15) which referred to both formal and informal risk management – see Figure 1 above.
This flowchart is essentially a decision tree for assessing risks and making decisions on those risks. It
indicates that, when there are clear rules in place for decision making, no risk management is
required and the relevant rules should be applied, without any flexibility. A GMP example here
might be when a Qualified Person (QP) in a manufacturing plant in the EU is deciding whether to
certify a batch for release or not. If the batch was out-of-specification for one attribute when QC
tested, the EU legal requirement, or rule, that batches which are not in line with the relevant
marketing authorisation may not be released should be followed. Risk Management in this situation
should not be applied during the batch disposition decision-making process. But when a clear rule is
lacking, the flowchart indicates that one may apply risk management in the decision-making process,
and it indicates that this may be formal or informal in nature. Here, the flowchart requires one to
answer three questions in order to decide whether formal or informal risk management should be
applied. These questions are:
•
•
•

What might go wrong?
What is the likelihood (probability) it will go wrong?
What are the consequences (severity)?

In cases where these three questions can be answered, the flowchart indicates that informal risk
management can be applied. And according to the flowchart, this involves initiating a risk
assessment, running risk control measures and documenting the results, decisions and actions.
When the above three questions cannot be answered, formal risk management should be applied.
This involves agreeing on a team, selecting a risk management tool, applying the QRM process,
documenting the steps that were carried out, and documenting the results, decisions and actions.
During the workshop discussions, the general view was that the flow-chart was not sufficiently clear
and none of the companies in attendance indicated that they had been applying it as an aide to their
decision making. The flowchart was regarded as providing little meaningful differentiation between
17
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what constitutes formal versus informal risk management. It implied that risk assessment and risk
control were to be performed when informal risk management was required. However, a team and a
risk management tool were required during formal risk management, where the QRM process was
to be followed. In relation to the risk assessment and risk control steps in an informal risk
management approach, the flowchart was regarded as being unclear. It seemed to imply that a risk
management tool was only to be used when performing formal risk management, even though the
majority of the tools specified in ICH Q9 actually relate to risk assessment and risk control activities,
which are positioned in the flowchart as informal risk management activities.
It was also considered that the flowchart was unclear as to where risk review and risk
communication might be applied. It made no direct reference to those two elements of QRM as per
ICH Q9, unless the wording “Carry out the risk management process” in the formal risk management
approach implied that all four elements (Risk Assessment, Risk control, Risk Review and Risk
Communication) of the QRM process were to be applied there.
Overall, the first workshop indicated a general lack of understanding of what constituted formality in
QRM, and that additional guidance in this area was clearly required. While a set of keywords had
been developed which illustrated to some extent what might be meant by formal QRM and informal
QRM, that was far from cohesive, it was sometimes contradictory, and it was generally difficult to
interpret.
•

Workshop No. 2 – March 2017

During the second workshop, the outputs and findings from the first workshop were reviewed, and
the discussion then centred on whether formality in QRM might better be understood by expressing
it in terms of rigour. The idea was that in less formal approaches to QRM, less rigour is generally
applied to the elements that make up the QRM process as per ICH Q9 (Risk Assessment, Risk control,
Risk Review and Risk Communication). There was general agreement that rigour could be a more
appropriate term to represent the difference between formal and informal QRM.
Work then moved to characterising what was meant by formal and informal QRM. It was suggested
that formal QRM can be characterised by the following statements:
•
•
•
•
•

Formal QRM is systems-focused rather than being focussed on evaluating the risks presented by
individual events.
Formal QRM is an end-to-end process, incorporating the four elements of QRM as per ICH Q9 Risk Assessment, Risk control, Risk Review and Risk Communication.
Risk Communication is embedded into each element of the QRM process when formal QRM is
being undertaken.
Formal QRM is structured, in terms of its use of SOPs and tools.
Formal QRM is an integral part of the Pharmaceutical Quality System (PQS), where the following
expectations apply:
QRM activities should be subjected to structured governance controls within the quality
system;
QRM outputs should be documented in a site Risk Register;
An escalation process to senior management should be in place for certain risk issues. (Note
that exactly which risk issues were of concern here were not determined);
Management Reviews and Product Quality Reviews (PQRs) should be regarded as QRM tools
in their own right.
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With regard to the use of tools, it was discussed how risk assessment tools are different from root
cause analysis tools and, while they are not the same, a strong approach to root cause analysis
supports risk assessment activities and should be encouraged.
In relation to informal QRM, it was observed during the workshop that this was more difficult to
characterise. It was suggested that informal QRM was more event-focused than systems-focussed,
and that it involved more stand-alone risk assessments than complete QRM reports. It was also
suggested that expressing formality in terms of the degree of rigour that is applied when assessing
and managing risks may be a useful way of differentiating between formal and informal QRM. It was
generally agreed that the level of rigour that is applied can also differ based on the degree of risk
that is considered to be present.
The discussions at the workshop suggested that both formal and informal QRM can have certain
elements in common:
•
•
•
•

Each can make use of facilitators and multi-functional teams, as required;
Each can make use of shop-floor evaluations of risks, where risk assessments need not
always be performed in meeting room settings;
Each needs to be supported by a documented process, but with different levels of formality,
as appropriate;
Each should be subject to training activities, including training on any QRM tools that are
used.

The question of whether formal QRM could be considered superior to informal QRM was discussed
in this workshop. As in the first workshop, no consensus was reached, but the majority view in both
workshops was that it was not superior. This was an interesting finding, and it was somewhat
unexpected. (During the discussions, some participants expressed the view that formal risk
assessments sometimes end up being only ‘tick box’ exercises, and of little value.)
The second workshop ended with an agreement that the topic of formality in QRM was of direct
relevance and interest to medicines manufacturers, and that clear regulatory guidance in this area
was needed. As at the first workshop, the participants agreed that the topic merited further study
and research, and it was suggested that the terminology relating to formality in QRM should be
reviewed, as perhaps that was where some of the difficulties in understanding this concept lay.
---------------- End of Appendix 1 ----------------
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